Effect of culture conditions on the chemosensitivity of ovarian cancer cell lines

Anti-Cancer Drugs

Volumn 17, Issue 8, 2006, Pages 913-919

  Fernando, Augusta ^a   Glaysher, Sharon ^a   Conroy, Mark ^a   Pekalski, Marcin ^a   Smith, Jason ^a   Knight, Louise A ^a   Nicolantonio, Federica Di ^a   Cree, Ian A ^a  

^a QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

Author keywords

Chemosensitivity; Ovarian cancer cell lines; Serum free culture conditions

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; CISPLATIN; CYTOTOXIC AGENT; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; METHOTREXATE; NAVELBINE; PACLITAXEL; POLYPROPYLENE; TOPOTECAN; TREOSULFAN; VINCRISTINE;

ARTICLE; CANCER CELL CULTURE; CANCER RESEARCH; CELL ADHESION; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; OVARY CANCER; OVARY TUMOR; PRIORITY JOURNAL; SOLID TUMOR; TUMOR GROWTH;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CULTURE MEDIA, SERUM-FREE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; OVARIAN NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 33748452491     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000224445.23953.d9     Document Type: Article

References (33)

1. Cree IA, Kurbacher CM. ATP based tumour chemosensitivity testing: assisting new agent development. Anticancer Drugs 1999; 10:431-435.
2. Sawyers CL, Sausville EA. Overview: the art of cancer drug screening: molecular target versus milieu-based screens. Curr Opin Investig Drugs 2002; 3:478-481.
3. Baguley BC, Marshall ES. In vitro modelling of human tumour behaviour in drug discovery programmes. Eur J Cancer 2004; 40:794-801.
4. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991; 83:757-766.
5. Freshney RI. Culture of animal cells: a manual of basic technique. New York: Wiley-Liss; 1994.
6. Cree IA, Pazzagli M, Mini E, Mazzei T, Hunter EM, Sutherland LA, et al. Methotrexate chemosensitivity by ATP luminescence in human leukemia cell lines and in breast cancer primary cultures: comparison of the TCA-100 assay with a clonogenic assay. Anticancer Drugs 1995; 6:398-404.
7. Cree IA, Petty RD, Sutherland LA, Hunter EMM, Subedi AMC, James EA, et al. Elucidation of molecular determinants of tumour chemosensitivity by ATP-based luminescence assay. In: Campbell AC, Stanley PE, Kricka LJ, editors. Chemluminescence and bioluminescence. Chichester: Wiley; 1994; 407-410.
8. Fidler IJ, Wilmanns C, Staroselsky A, Radinsky R, Dong Z, Fan D. Modulation of tumor cell response to chemotherapy by the organ environment. Cancer Metastasis Rev 1994; 13:209-222.
9. Van Diest PJ, Baak JP, Brugghe J, Van De Burg ME, Van Oosterom AT, Neijt JP. Quantitative pathologic features as predictors of long-term survival in patients with advanced ovarian cancer treated with cisplatin. Int J Gynecol Cancer 1994; 4:174-179.
10. Andreotti PE, Linder D, Hartmann DM, Cree IA, Pazzagli M, Bruckner HW. TCA-100 tumour chemosensitivity assay: differences in sensitivity between cultured tumour cell lines and clinical studies. J Biolumin Chemilumin 1994; 9:373-378.
11. Cree IA, Andreotti PE. Measurement of cytotoxicity by ATP-based luminescence assay in primary cell cultures and cell lines. Toxicology In Vitro 1997; 11:553-556.
12. Hanahan D, Weinberg RA. The hallmarks of cancer [review]. Cell 2000; 7:57-70.
13. Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, et al. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 1995; 55:5276-5282.
14. Sharma S, Neale MH, Di Nicolantonio F, Knight LA, Whitehouse PA, Mercer SJ, et al. Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma. BMC Cancer 2003; 3:19.
15. Cree IA, Kurbacher CM, Untch M, Sutherland LA, Hunter EM, Subedi AM, et al. Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Anticancer Drugs 1996; 7:630-635.
16. Hunter EM, Sutherland LA, Cree IA, Dewar JA, Preece PE, Wood RA, et al. Heterogeneity of chemosensitivity in human breast carcinoma: use of an adenosine triphosphate (ATP) chemiluminescence assay. Eur J Surg Oncol 1993; 19:242-249.
17. Hartley JA, O'Hare CC, Baumgart J. DNA alkylation and interstrand cross-linking by treosulfan. Br J Cancer 1999; 79:264-266.
18. Peters GJ, Ruiz van Haperen VW, Bergman AM, Veerman G, Smitskamp-Wilms E, van Moorsel CJ, et al. Preclinical combination therapy with gemcitabine and mechanisms of resistance. Semin Oncol 1996; 23:16-24.
19. Knight LA, Conroy M, Fernando A, Polak M, Kurbacher CM, Cree IA. Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay. Anticancer Drugs 2005; 16:969-976.
20. Guppy AE, Nathan PD, Rustin GJ. Epithelial ovarian cancer: a review of current management. Clin Oncol 2005; 17:399-411.
21. Gabra H, Redman C, Byrom J. Ovarian cancer. Clin Evid 2003; 10:2170-2183.
22. National Centre for Clinical Excellence. Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer. NICE Technology Appraisal 2005; 91. http://www.nice.org.uk/pdf/TA091guidance.pdf.
23. Konecny G, Crohns C, Pegram M, Felber M, Lude S, Kurbacher C, et al. Correlation of drug response with the ATP tumor chemosensitivity assay in primary FIGO stage III ovarian cancer. Gynecol Oncol 2000; 77:258-263.
24. See HT, Kavanagh JJ, Hu W, Bast RC. Targeted therapy for epithelial ovarian cancer: current status and future prospects. Int J Gynecol Cancer 2003; 13:701-734.
25. Dunton CJ. New options for the treatment of advanced ovarian cancer. Semin Oncol 1997; 24:S5-S11.
26. Miglietta L, Amoroso D, Bruzzone M, Granetto C, Catsafados E, Mammoliti S, et al. Paclitaxel plus ifosfamide in advanced ovarian cancer: a multicenter phase II study. Oncology 1997; 54:102-107.
27. Lincet H, Poulain L, Remy JS, Deslandes E, Duigou F, Gauduchon P, et al. The p21(cip1/waf1) cyclin-dependent kinase inhibitor enhances the cytotoxic effect of cisplatin in human ovarian carcinoma cells. Cancer Lett 2000; 161:17-26.
28. Rose P, Mossbruger K, Fusco N, Smrekar M, Eaton S, Rodriguez M. Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma. Gynecol Oncol 2003; 88:17-21.
29. Nagourney RA, Brewer CA, Radecki S, Kidder WA, Sommers BL, Evans SS, et al. Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. Gynecol Oncol 2003; 88:35-39.
30. Zhao J, Kim JE, Reed E, Li QQ. Molecular mechanism of antitumor activity of taxanes in lung cancer [review]. Int J Oncol 2005; 27:247-256.
31. McDaid HM, Johnston PG, McDaid HM, Johnston PG. Synergistic interaction between paclitaxel and 8-chloro-adenosine 3′,5′-monophosphate in human ovarian carcinoma cell lines. Clin Cancer Res 1999; 5:215-220.
32. Di Nicolantonio F, Mercer SJ, Knight LA, Gabriel FG, Whitehouse PA, Sharma S, et al. Cancer cell adaptation to chemotherapy. BMC Cancer 2005; 5:78.
33. Duan Z, Lamendola DE, Duan Y, Yusuf RZ, Seiden MV. Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines. Cancer Chemother Pharmacol 2005; 55:277-285.